Algeta applies to join Oslo Stock Exchange

5 February 2007

Norway-based Algeta ASA, a therapeutics firm dedicated to novel anticancer agents based on active radionuclides, says that it has applied for listing on the Oslo Stock Exchange. The company explained that it had taken the decision in order to obtain funding for the Phase III clinical development of its lead product, Alpharadin, a novel radiopharmaceutical based on the alpha particle-emitter radium-223.

In Phase II studies, the drug demonstrated the ability to delay the progression of prostate cancer, as well as reducing the extent and effect of metastasis. The company added that it will present full data from its Phase II program at the upcoming meeting of the American Society of Clinical Oncology's prostate cancer symposium in Orlando, USA, later this month.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight